Thank you for this incredible honor of the Andrew C. Novick Award. Immensely humbled by this recognition from the Kidney Cancer leadership. 

Receiving this is particularly poignant for me, as I was trained by Robert Uzzo for whom Dr. Novick was an absolutely critical mentor.…

Researchers at Fox Chase just published the results of a phase 1 study that showed reduced immune-related side effects with immune checkpoint inhibitor drug Nivolumab. Read more from lead study author, Dr. Matthew Zibelman: bit.ly/3PuZyd4

💉Immunotherapy for castration-resistant #prostatecancer ?

CAR T-cells and BiTEs targeting PSMA may just be the future

🔥An open access review article by Kayvan (Kevin) Zarrabi, MD MS

Link🔗➡️ bit.ly/3KvQ4eO

Vivek Narayan
Matthew Zibelman
Ben Miron
Babar Bashir MD, MS
Sidney Kimmel Cancer Center – Jefferson Health

Survival outcomes in patients with muscle-invasive #BladderCancer receiving neoadjuvant chemotherapy stratified by the number of cycles. Presented by @AnumitaChakrab8 Temple IM Residency. #ASCO23 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/45OvCi7 ASCO

Happening now. Ben Miron Fox Chase Cancer Center Department of Urology Fox Chase Cancer Center educating us about real world data and relevance to #RCC #ASCO2023

Namrata (Neena) Vijayvergia MD putting PROs into context for patients with hepatobilliary tumors, and the importance of patient's centered care! #ASCO2023

Honored to be giving my first ASCO presentation along side Dena Battle and Dr Wulff-Burchfield in an exciting session touching on some ways we can refocus our trials to put our patients battling GU cancers first! Please come check us out! #ASCO23 meetings.asco.org/2023-asco-annu…

⚡️Dr. Ben Miron and I discuss the practice informing presentation by Toni Choueiri, MD ASCO #GU23

Is there a potential predictive biomarker of treatment efficacy in renal cell cancer?

👇
vumedi.com/video/asco-gu-…

Great shot!! Congrats Ben Miron Julia Judd, DO, Cyrus Mazidi. Hope it wasn’t all stats and schemas. But when you get back, gotta get these trials up and running!!! Fox Chase Cancer Center

New Platinum Priority Editorial from Ben Miron and Daniel M. Geynisman Fox Chase Cancer Center

Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma

buff.ly/3HSnamq

Together with a 🌟team of #bladdercancer experts - we wrote a review of/wish list for #clinicaltrials investigating ways to📈QoL without sacrificing outcomes in tx of #MIBC via #bladderpreservation and #bladdersparing authors.elsevier.com/a/1f0qL,yeo3ud… (no paywall)

Please support AREN1721 for TFE/Translocation RCC #COG #ECOGACRIN

Amer. Urol. Assn. Thanks to Amer. Urol. Assn. & Jay Raman for the opportunity to discuss Kidney Cancer in Adolescents&Young Adults … please remember AREN1721 for patients w TFE+RCC (Nivo vs Nivo+Axi) … DM me with any questions. clinicaltrials.gov/ct2/show/NCT03… Brian Shuch, MD Phillip Pierorazio Alexander Kutikov MD

Neeraj Agarwal, MD, FASCO Journal of Clinical Oncology National Cancer Institute SWOG Cancer Research Network OncoAlert Lucky Lara University of Utah Huntsman Cancer Institute Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Petros Grivas Neli Ulrich, PhD GU Cancer Research Program @HuntsmanCancer Arun Azad Vivek Subbiah, MD PCF Science Tanya Dorff Congratulations! Great to see this published. We have many pts still on this study Fox Chase Cancer Center site PI Matthew Zibelman

#clinicaltrials advance our field and none would be possible without our amazing research teams back home. Courtney Lambert, our Clinical Research Nurse Fox Chase Cancer Center Department of Urology joined us this year at #GU22 to see the results of her study presented by PI Matthew Zibelman #teamwork

Elizabeth Plimack MD Fox Chase Cancer Center Department of Urology Matthew Zibelman Fern Anari pooja ghatalia Colleen Tetzlaff Fox Chase Cancer Center Department of Urology clinical research team, Courtney included, are incredible! Care so much about and for our patients and such a pleasure to work with them in clinic.

Fox Chase's Dr. Matthew Zibelman led a phase I/II study that investigated the safety & efficacy of combining the tyrosine kinase inhibitor axitinib w/ the immune checkpoint inhibitor agent nivolumab.

Learn more about the study that was presented at #GU22 : bit.ly/3s1avre

Axitinib-nivolumab with ORR ~70% and disease control in >90%! Congrats Matthew Zibelman Elizabeth Plimack MD on completing this great effort!

Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine jnccn.org/view/journals/… very proud of our team Fox Chase Cancer Center and the support National Comprehensive Cancer Network (NCCN) Thank you to our #cancer patients and their families

Fantastic editorial and perspective by Ben Miron Laura Bukavina and Elizabeth Plimack MD